Resources

Andrew Merrison from FI Group shares his knowledge about the new rule changes HMRC has put in place concerning overseas costs about biotech.

Will James and Robyn Trigg from Osborne Clarke look at how the UPC's practice and procedure has developed since it began operations in June 2023.

In this blog, BIA member Brainomix, following its series C round, answers questions on the company's origins and future trajectory.

University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments.

Co-designing new networks with research users is critical to delivering the full scientific and commercial value of NHS health data.

The data the biotech industry generates, consumes and shares is very often not only extremely sensitive (expensive to create, the product of some of the finest minds and technically focused facilities on the earth, in some cases connectable to the very fabric of humanity), it’s impossible to de-sensitise once lost to an attacker. 

OMass Therapeutics Strengthens its Leadership Team with the Promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical

Imperial, the leading global science university, is achieving a major step up in its life sciences capacity at its White City Deep Tech Campus through a major new joint venture with Bruntwood SciTech.

We are excited to welcome the newly elected members of the BIA Board of Directors, who will bring fresh insights and expertise to help drive our mission forward. Nick Gardiner shares his perspective on the importance of these appointments and the unique value each new Director brings to the BIA.

The UK biotech sector demonstrated encouraging resilience in the third quarter of 2024 raising a total of £808 million in venture capital and public financing. Read our latest report to find out more.

The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.

The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.

In this insightful blog, Louis Taylor, CEO of the British Business Bank, explores how the Mansion House reforms and increased pension fund investments could unlock billions in domestic capital, fueling the next generation of UK innovators.

Symbiosis Pharmaceutical Services Ltd announces the purchase of new premises in Stirling, Scotland, UK. The additional space will double the total footprint of the company across the four facilities that it will operate from, increasing manufacturing capacity by 50% in the short-term.

Steve Bates OBE, CEO of the BIA, responded to the announcement of a new Regulatory Innovation Office.

The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.